TITLE:
Spermotrend Improves Semen Quality and Infertility in Men with Varicocele —Spermotrend and Male Infertility
AUTHORS:
Melida Aguilar Chamorro, Sergio Antonio Vargas Collado, David Marquez Soriano
KEYWORDS:
Antioxidants, Dietary Supplementation, Male Infertility, Spermatogenesis, Varicocele, Pygeum africanum
JOURNAL NAME:
Advances in Reproductive Sciences,
Vol.12 No.2,
March
11,
2024
ABSTRACT: Background: Infertility affects 8% - 12% of couples
globally, with approximately half of the cases reported in males. Oxidative stress
is a common factor increased in the varicocele condition and particularly affects
spermatozoa, due to their sensitivity to oxidative signals and testicular hypotrophy.
The objective of this clinical trial is to study the effectiveness of Spermotrend
in the improvement of sperm parameters in male infertility. Methods: A total
of 170 males aged > 18 years
with a diagnosis of infertility and varicocele were consecutively enrolled in a
Phase II, open-label clinical trial. Spermotrend was administered 1 capsule (450
mg) orally every 8 hours for 6 months and was evaluated through semen analysis at
4 and 6 months of follow-up. Results: The trial results show a significant
improvement following the administration of Spermotrend over 6 months in sperm concentration
(44.1% at baseline vs. 64.1% at 6 months), sperm survival (28.2% with sperm survival
≥ 2 hours vs.56.5%), normalization of sperm morphology (31.2% vs. 72.9%). Varicocele
condition decreased in all patients and, by the end of the study, 55.3% of patients
had normal venous flow and dilation. Only 5.9% of the patients showed grade 2 varicocele
at the end of the study, while 38.8% showed grade 1 varicocele, with no patients
showing grade 3 varicocele. Regarding testicular hypotrophy, 90.6% of the patients
completed the study with normalized testicular volume by recovering normal venous
flow. Conclusion: A short-term course of Spermotrend may significantly improve
sperm parameters associated with male infertility. Clinical Trial Registration: The clinical trial protocol was registered in the international
clinical trial registry, ClinicalTrials.gov, with the code: NCT05222841 on
15/06/2021.